The Cytokine Storm Company

Lenzilumab, COVID-19, and Cytokine Storm

Q&A Series

About Us

We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody.


Are you or a loved one seeking a treatment for COVID-19?



To learn about Humanigen's Phase 3 Clinical Trial


Statement from Humanigen
Updated December 15, 2020

Emergency Use Authorization of Pfizer and BioNTech’s COVID-19 vaccine represents a significant step forward in COVID-19 prevention and all of us at Humanigen applaud the collective efforts that went in to making this a reality. 

While we celebrate this important milestone, we also recognize that with over 100 thousand hospitalized  in the U.S. and more than 73 million cases of COVID-19 worldwide, the need for COVID-19 therapeutics remains critical and we must continue to advance the development and manufacturing of therapeutics to turn the tide in this pandemic. 

Humanigen is intensely focused on developing our investigational Phase 3 treatment candidate, lenzilumab™, to prevent and treat an immune hyper-response called cytokine storm, which has been responsible for some of the most severe and deadly symptoms of COVID-19. 


To learn more about our lead treatment candidate, lenzilumab or to find a clinical trial near you, visit:


"The more original a discovery the more obvious it seems afterwards."

Arthur Koestler

Follow Us

  • Twitter
  • LinkedIn
  • Facebook

©2021 Humanigen, Inc.  All rights reserved